pcn poster

Posters

Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-world Data for the 1-Month and 3-Month Formulations

Compare efficacy of the three paliperidone palmitate (PP) long-acting injectable formulations for relapse prevention in schizophrenia: Relapse in schizophrenia has pronounced consequences...

Ibrahim Turkoz , PhD;

10/26/2023

Reliable, Scalable Assessment in Routine Practice-Implementing Rapid Clozapine Blood Levels in the Real World

The project's objective was to implement rapid clozapine blood level testing at a large academic medical center. Upon implementation, the time to receive test results improved from 87.4 h...

Megan J. Ehret , PharmD, MS, BCPP;

10/26/2023

Safety and Efficacy of KarXT in Schizophrenia in the Randomized, Double-Blind, Placebo-Controlled, Phase 3 EMERGENT-3 Trial

In the EMERGENT-3 phase 3 trial, KarXT, a combination of xanomeline (M1/M4 muscarinic receptor agonist) and trospium chloride (muscarinic receptor antagonist), demonstrated significant ef...

Inder Kaul , MD;

10/26/2023

Real-World Antipsychotic and Vesicular Monoamine Transporter Type 2 Inhibitor Treatment Patterns in Patients Newly Diagnosed With Tardive Dyskinesia

Antipsychotic (AP) and vesicular monoamine transporter type 2 inhibitor (VMAT2i) treatment patterns post-tardive dyskinesia (TD) diagnosis are unclear. Deutetrabenazine (DTBZ) is a VMAT2i...

Marko Mychaskiw , PhD;

10/26/2023

Prevalence of Abnormal CYP2D6 Phenotypes in those with Treatment Resistant Depression

In a retrospective analysis of 356 patients, abnormal CYP2D6 variants were significantly more prevalent in those with treatment-resistant depression than those with other types of depress...

Kielan C. Lovell ;

10/26/2023

Prevalence of concomitant medications among patients with schizophrenia prescribed atypical antipsychotics

The prevalence of concomitant medication use in patients with schizophrenia has not been well established. This study aimed to bridge this gap by evaluating the annual prevalence of conco...

Monika Semwal , PhD;

10/26/2023

Qelbree® (viloxazine extended-release capsules): Final Results of the Long-Term, Phase 3, Open-Label Extension Trial in Adults With Attention-Deficit/Hyperactivity Disorder

Final results of a long-term, open-label extension of a pivotal phase 3 study leading to FDA-approval of viloxazine extended-release capsules (Qelbree®) in adults.

Andrew J. Cutler , MD;

10/26/2023

Qualitative Study to Assess the Patient Perspective on Anhedonia Symptoms and Impacts in Major Depressive Disorder

This qualitative research study assessed the patient experience of anhedonia and its impacts among patients with MDD. Semi-structured concept elicitation interviews were conducted with 1...

Heather M. Rozjabek , PhD;

10/26/2023

Rapid Relief of Complicated Grief State in a Marital Dyad By Application of Ketamine-facilitated Couples Psychotherapy

Psychedelic therapy was offered to a couple 'cognitively stuck' on their dyadic journey through their grief work. On, their second mutual ketamine-experience they both entered the transp...

Frank W. Meissner , MD, RDMS;

10/26/2023

Precision Medicine in Depression: Response to Antidepressants is Associated with the Interplay Between Genetic variants and Gene Expression Levels in Patient-Derived Neurons

We present a study on the interplay between genetic variants and gene expression levels in depressed patients’ neurons and its association with antidepressant response. Neuronal expressio...

Daphna Laifenfeld , PhD;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products